Obstetrics & Gynecology Track the topics, authors and articles important to you
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Obstetrics & Gynecology 1989;73:786-792
© 1989 by The American College of Obstetricians and Gynecologists
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by FEUER, G. A.
Right arrow Articles by CALANOG, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by FEUER, G. A.
Right arrow Articles by CALANOG, A.

Normal-Sized Ovary Carcinoma Syndrome

GERALD A. FEUER, MD, MARIA SHEVCHUK, MD and ANTHONY CALANOG, MD

From the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, State University of New York, Health Science Center at Brooklyn; the Department of Pathology, Columbia-Presbyterian Hospital; and the Department of Gynecologic Oncology, Lenox Hill Hospital, New York, New York

Abstract

A clinical situation occasionally presents in which diffuse metastatic disease of the peritoneal cavity is noted, but the ovaries are of normal size, with or without a fine granularity on their external surface. We term this clinical phenomenon the "normal-sized ovary carcinoma syndrome." In an effort to study this dilemma, the clinical records and pathology slides were reviewed for 11 cases identified from 1976-1987. Four diagnostic groups were identified: mesothelioma (four patients), "extragonadal müllerian" tumors (two patients), metastatic tumors of unknown origin (four patients), and ovarian carcinoma (one patient). The survival for each of the first three groups is usually less than 1 year. Improved survival for mesotheliomas may be achieved with a combination of radiotherapy, an adriamycin-based chemotherapy regimen, and debulking surgery. A successful treatment strategy for serous surface papillary carcinoma has not been identified. Patients with metastatic tumors of unknown origin should either be treated with 5-fluorouracil or should not be treated at all. In order to discern the site of origin, satisfactory perioperative radiologic assessment, fastidious surgical exploration, and adequate communication between the surgeon and the pathologist are necessary.




This article has been cited by other articles:


Home page
JCOHome page
J. W. Carlson, A. Miron, E. A. Jarboe, M. M. Parast, M. S. Hirsch, Y. Lee, M. G. Muto, D. Kindelberger, and C. P. Crum
Serous Tubal Intraepithelial Carcinoma: Its Potential Role in Primary Peritoneal Serous Carcinoma and Serous Cancer Prevention
J. Clin. Oncol., September 1, 2008; 26(25): 4160 - 4165.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. Emoto, R. Fujimitsu, H. Iwasaki, and T. Kawarabayashi
Diagnostic Challenges in Patients With Tumors: CASE 3. NORMAL-SIZED OVARIAN CANCER DETECTED BY COLOR DOPPLER ULTRASOUND USING A MICROBUBBLE CONTRAST AGENT
J. Clin. Oncol., October 1, 2003; 21(19): 3703 - 3705.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1989 by the American College of Obstetricians and Gynecologists.